HIPRA COVID-19 Vaccine Description

HIPRA COVID-19 Vaccine is a heterologous recombinant heterodimer protein-based vaccine. The active component of the HIPRA Covid-19 VACCINE is a heterologous recombinant heterodimer protein that emulates the receptor binding domain (RBD) of the Spike (S) protein of the Alpha and Beta variants of the SARS-Cov-2 virus. The antigen, which is the active component of the vaccine, requires an adjuvant to amplify and enhance the immune response. In the HIPRA Covid-19 vaccine, the adjuvant is an oil-in-water emulsion, which has already demonstrated its efficacy and safety in many other vaccines.

The vaccine is inoculated into the body triggering the immune response by producing antibodies and activating memory cells. When a vaccinated person is exposed to the virus, the generated antibodies will neutralize the virus, thereby preventing the development of the severe disease.

In 2021 the new Human Health division was created to develop new innovative products in Spain.

With the aim of positioning HIPRA as a company specializing in vaccines, the HIPRA Committee of Experts on the Covid-19 Vaccine was set up on July 8, 2022, coinciding with the first work meeting that took place at HIPRA headquarters in Spain, at Avenida la Selva 135, 17170 Amer (Girona), Spain.

HIPRA COVID-19 Indication

The vaccine is indicated to prevent illness from the SARS-CoV-2 coronavirus that causes COVID-19. The vaccine triggers an immune response by producing antibodies and activates memory cells. When a vaccinated person is exposed to the virus, the generated antibodies will neutralize the virus, thereby preventing the development of the severe disease.

HIPRA COVID-19 Storage

The HIPRA vaccine is stored between 2 and 8º C, facilitating its logistics and distribution. It is a ready-to-use vaccine administered via the intramuscular route.

HIPRA COVID-19 News

August 2, 2022 - The EU Health Commission has signed a contract to procure the HIPRA COVID-19 protein vaccine.

July 19, 2022 - HIPRA's COVID-19 vaccine induces a good neutralizing antibody response against the BA.2, BA.4, and BA.5 subvariants of Omicron.

May 9, 2022 - HIPRA started a Phase III clinical trial of the Covid-19 vaccine in immunocompromised people after the Spanish Agency for Medicines and Health Products (AEMPS) authorized it.

HIPRA COVID-19 Clinical Trials

The HIPRA Covid-19 vaccine has undergone rigorous clinical studies before being approved for human use by the regulatory authorities. These clinical trials, classified by phases I, II, and III, are used to determine the vaccine's efficacy, safety, and tolerability. The phases for the trials are as follows:

Phase 1/2a: The objective is to determine the appropriate dose and study the safety and immunogenicity of the vaccine.

Phase 2b: The objective is to determine the immunogenicity and safety of the vaccine.

Phase 3: The objective is to assess the safety and tolerability of the vaccine.